Matching articles for "RiVive"
In Brief: A New OTC Naloxone Nasal Spray (RiVive)
The Medical Letter on Drugs and Therapeutics • March 18, 2024; (Issue 1698)
The FDA has approved RiVive (Harm Reduction
Therapeutics), a 3-mg naloxone nasal spray, as
an over-the-counter (OTC) product for emergency
treatment of opioid overdose. Two 4-mg naloxone
nasal spray...
The FDA has approved RiVive (Harm Reduction
Therapeutics), a 3-mg naloxone nasal spray, as
an over-the-counter (OTC) product for emergency
treatment of opioid overdose. Two 4-mg naloxone
nasal spray formulations, Narcan and one of its
generics, were approved for OTC sale in 2023.
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
The FDA has approved an intranasal formulation of
the opioid antagonist nalmefene (Opvee – Indivior) for
emergency treatment of known or suspected opioid
overdose in persons ≥12 years old. Nalmefene,...
The FDA has approved an intranasal formulation of
the opioid antagonist nalmefene (Opvee – Indivior) for
emergency treatment of known or suspected opioid
overdose in persons ≥12 years old. Nalmefene, which
is available by prescription, is the second opioid
antagonist to become available as a nasal spray
for this indication; the first was naloxone, which is
now available for sale over the counter (Narcan, and
generic). Other nasal spray formulations of naloxone
and injectable formulations of nalmefene and
naloxone are available by prescription (see Table 2).
Addendum: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • October 2, 2023; (Issue 1686)
Since the publication of our articles entitled Drugs for
Opioid Use Disorder and In Brief: Over-the-Counter
Narcan Nasal Spray earlier this year, Narcan (Emergent),
a nasal spray that delivers 4 mg of the...
Since the publication of our articles entitled Drugs for
Opioid Use Disorder and In Brief: Over-the-Counter
Narcan Nasal Spray earlier this year, Narcan (Emergent),
a nasal spray that delivers 4 mg of the opioid antagonist
naloxone, has become available for sale over the counter
(OTC). According to the manufacturer, the retail price for
a box containing 2 doses is $44.99. Some insurance
companies have announced plans to cover OTC
purchase of the drug for their members.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • September 4, 2023; (Issue 1684)
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.